MaaT Pharma Announces Promising Final Data Readout for Phase 1b Evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS)
BUSINESS WIRE)--Regulatory News:
These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also highlight the therapeutic potential of microbiome modulation beyond oncology.
MaaT Pharma (EURONEXT: MAAT – the 'Company'), a clinical-stage biotechnology company and a leader in the development of Microbiome Ecosystem Therapies TM (MET) dedicated to enhancing survival for patients with cancer through immune modulation, announced additional findings following full data readout for the exploratory single-arm, open-label Phase 1b clinical trial named IASO (NCT05889572) evaluating MaaT033 in Amyotrophic Lateral Sclerosis (ALS).
, the Company announced that the trial had met its primary endpoint assessing the safety and tolerability of MaaT033 with multiple doses, following the independent Data Safety and Monitoring Board (DSMB) conclusion. As a reminder, the exploratory Phase 1b trial enrolled a total of 15 participants across two centers in France Hôpital de la Pitié-Salpêtrière – AP-HP and the University Hospital of Lille. An external Scientific Advisory Committee took place at the end of March 2025 to review the full data. Below are the key takeaways from the Committee's review:
MaaT033 demonstrated a favorable safety and tolerability profile, supported by biomarker and microbiome analyses.
A rapid and sustained engraftment of bacterial species from MaaT033 was observed, mostly occurring within the first month and maintained during the 1-month follow-up period.
A slower rate of disease progression (based on ALSFRS-R slopes) was noted to be interpreted with caution given the short follow up, limited sample size and single-arm Phase 1b design. The ALSFRS-R is a standard functional scale in ALS trials to track the progression of the disease. The slope reflects how many points are 'lost' (=disease progression) per month. In the final data readout for the IASO trial, the following was observed for the ALSFRS-R Total score slope:
From first symptoms to baseline, the median slope was –0.7 points/month (range: –1.2 to –0.3)
From baseline to Day 84 (D84), the median slope slowed to –0.3 points/month (range: –2.4 to +1.0)
No variation at D84 in the levels of neurofilaments, a marker associated with neuronal injury in ALS.
In addition, the Scientific Advisory Committee provided insights regarding the best population to target in a Phase 2 trial.
'These encouraging findings from the IASO Phase 1b trial confirm the favorable safety and tolerability profile of MaaT033 in ALS patients. They also highlight the therapeutic potential of microbiome modulation beyond oncology and open new avenues for development in neurodegenerative diseases, as evidence continues to grow around the gut-brain connection," said Gianfranco Pittari, MD, PhD, Chief Medical Officer of MaaT Pharma.
The study was conducted in close collaboration with the French patient association Tous en Selles contre la SLA (TECS), highlighting the essential role of patients and their advocates in advancing science, and with the support of experts from the French academic networks FILSLAN and ACT4ALS-MND.
'Recognizing the significant unmet medical need in ALS and with the will to support those affected, we applied our discovery platform to this new disease area, demonstrating its potential beyond our primary focus in oncology with encouraging Phase 1 data. In light of the Company's strict financial discipline, and considering the recent successes achieved in oncology, we are actively seeking partners with a focus on ALS and the financial capacity to support new options to fight this disease," stated Hervé Affagard, CEO and co-founder of MaaT Pharma.
–--
About MaaT033
MaaT033, a standardized, donor-derived, high-richness, high-diversity oral Microbiome Ecosystem Therapy TM containing anti-inflammatory Butycore TM species, is currently being developed as an adjunctive therapy to improve overall survival in patients receiving HSCT and other cellular therapies. MaaT033 is developed with the "pooling" technology, which allows pooling donations from multiple donors to create a standardized product with high microbial richness and diversity. It aims to ensure optimal microbiota function and to address a larger patient population in a chronic setting. MaaT033 has been granted Orphan Drug Designation by the European Medicines Agency (EMA).
About Amyotrophic Lateral Sclerosis
Amyotrophic Lateral Sclerosis (ALS), also known as Lou Gehrig's disease in the US and Charcot's disease in Europe, is a progressive neurodegenerative disorder affecting motor neurons in the brain and spinal cord. This leads to muscle weakness, loss of voluntary movement, and eventually, paralysis and on an average lead to death in 3 to 5 years. ALS could affect up to 60,000 patients in US and EU by 2040 and has currently no curative treatment and few symptomatic treatments.
About MaaT Pharma
MaaT Pharma is a leading, late-stage clinical company focused on developing innovative gut microbiome-driven therapies to modulate the immune system and enhance cancer patient survival. Supported by a talented team committed to making a difference for patients worldwide, the Company was founded in 2014 and is based in Lyon, France.
As a pioneer, MaaT Pharma is leading the way in bringing the first microbiome-driven immunomodulator in oncology. Using its proprietary pooling and co-cultivation technologies, MaaT Pharma develops high diversity, standardized drug candidates, aiming at extending life of cancer patients. MaaT Pharma has been listed on Euronext Paris (ticker: MAAT) since 2021.
Forward-looking Statements
All statements other than statements of historical fact included in this press release about future events are subject to (i) change without notice and (ii) factors beyond the Company's control. These statements may include, without limitation, any statements preceded by, followed by, or including words such as 'target,' 'believe,' 'expect,' 'aim', 'intend,' 'may,' 'anticipate,' 'estimate,' 'plan,' 'project,' 'will,' 'can have,' 'likely,' 'should,' 'would,' 'could' and other words and terms of similar meaning or the negative thereof. Forward-looking statements are subject to inherent risks and uncertainties beyond the Company's control that could cause the Company's actual results or performance to be materially different from the expected results or performance expressed or implied by such forward-looking statements.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
8 hours ago
- Yahoo
ALS Walk raises over $100k
(WHTM) — Dozens came out to Hershey for the 2025 ALS Walk on Saturday. It was held at the Hershey Middle School on Homestead Road. The walk raises money to help fight the disease. Download the abc27 News+ app on your Roku, Amazon Fire TV Stick, and Apple TV devices Over $100,000 was collected. Copyright 2025 Nexstar Media, Inc. All rights reserved. This material may not be published, broadcast, rewritten, or redistributed.
Yahoo
15 hours ago
- Yahoo
Britain to allocate $116 billion to R&D in spending plan
LONDON (Reuters) -British finance minister Rachel Reeves will allocate 86 billion pounds ($116 billion) in this week's spending review to fund research and development, the Department for Science, Innovation and Technology (DSIT) said on Sunday. It said the package, funding everything from new drug treatments and longer-lasting batteries to artificial intelligence breakthroughs, would be worth over 22.5 billion pounds a year by 2029/30, driving new jobs and economic growth. Reeves will divide more than 2 trillion pounds ($2.7 trillion) of public money between her ministerial colleagues on Wednesday, making choices that will define what the year-old Labour government can achieve in the next four years. The DSIT said the announcement on R&D follows Reeves' commitment last week to 15.6 billion pounds of government investment in local transport in city regions in the Northern England, Midlands and the South West. ($1 = 0.7398 pounds)
Yahoo
2 days ago
- Yahoo
RFK Jr. will ‘end the war' against alternative medicine at the FDA, from stem cell therapy to chelation. Here's what to know
Health and Human Services Secretary Robert F. Kennedy, Jr. doubled down on his support for non-pharmaceutical health treatments during a recent podcast appearance, saying, 'We're going to end the war at the FDA against alternative medicine.' Speaking on the Ultimate Human podcast with host Gary Brecka, a 'renowned Human Biologist, biohacker, and longevity expert,' according to the website, Kennedy said he would fix the U.S. Food and Drug Administration's bias against the following: stem cell treatments, chelating drugs, vitamins and minerals, amino acids, peptides, and hyperbaric chambers. 'Our position is that the FDA has a job: Just do the science on these kinds of issues and then tell the public what they've learned from the science … but don't tell physicians what they can and cannot prescribe,' he said. And as far as the patients go, he said, 'If you want to take an experimental drug … you ought to be able to do that.' RFK Jr. added, 'We don't want to have the Wild West. We want to make sure that information is out there. But we also want to respect the intelligence of the American people' to decide what treatments will benefit them the most. He acknowledged that, with this approach, there will be 'charlatans' as well as 'people who have bad results' from various alternative treatments. 'But ultimately,' he said, 'you can't prevent that either way, and leaving the whole thing in the hands of pharma is not working for us.' Brecka called Kennedy's pronouncements 'music to my ears.' Below, what you need to know about the alternative therapies RFK Jr. is advocating for. What is it: It's a way to repair diseased or injured tissue in the body using stem cells—cells that can self-renew or become other types of tissues—typically grown in a lab, manipulated, and then be implanted into the patient. What it does: Though it's considered to be largely experimental, the FDA does permit stem cell therapies for blood and immune disorders. Leukemia, lymphoma, neuroblastoma, and multiple myeloma, for example, are also often treated this way, with bone marrow treatments, which are backed by decades of science. Other types of the treatment are still in clinical trials, while more and more wellness centers are offering the treatment for unapproved reasons, using cells drawn from the patient's body and injected back in without manipulation for everything from autism and ALS to Parkinson's and better skin, according to the New York Times. Kennedy told Brecka that he received the treatment for his voice disorder, spasmodic dysphonia, and that it helped him 'enormously,' but that he had to go to Antigua to access it. Risks: For starters, wellness clinic treatments cannot guarantee they are using actual stem cell, reported the Times. And improper injections can lead to a host of terrible consequences—clots, infections, blindness, and even the formation of tumors, which the FDA warned of in 2021. What it is: Chelation involves the use of certain chemicals to remove toxic heavy metals, such as mercury and lead, from the body; all FDA-approved chelation therapy products require a prescription and can only be used safely under the supervision of a healthcare practitioner. What it does: Some alternative medicine practitioners offer chelation therapy, through pill or injection, as a way to treat Alzheimer's, autism, diabetes, high blood pressure, or Parkinson's disease, all of which are unapproved and risky. Children's Health Defense, founded by Kennedy, has written about chelation as a way to treat autism, which compares 'autism with mercury poisoning' due to childhood vaccines that contained the preservative thimerosal (largely mercury) before it was removed in 2001. Some flu shots still contain the preservative, but, says the Centers for Disease Control and Prevention, 'There is no evidence of harm caused by the low doses of thimerosal in vaccines.' Risks: The FDA warns specifically about using chelation therapy for autism, and notes, 'Chelating important minerals needed by the body can lead to serious and life-threatening outcomes.' While minor risks may include fever, headache, muscle pain, and nausea or vomiting, severe reactions range from heart failure and kidney damage to respiratory failure and seizures, according to the Cleveland Clinic. What they are: Dietary supplements in almost every letter of the alphabet, from A to zinc, are over-the-counter pills or liquids that contain nutritional boosts of vitamins and minerals. What they aim to help: Vitamin and mineral supplements aim to fill in with necessary nutrients that a person is not getting through food—though nutritionists believe that healthy food is the best source of such vitamins and minerals. Studies have found supplements may help with practically any issue under the sun—energy, heart issues, cognitive function, gut health, sleep, and more. Risks: The U.S. Food and Drug Administration regulates supplements, but doesn't approve them for safety or effectiveness before they are sold to the public. Some may cause liver damage and toxicity, while others may just be a waste of money. What it is: Amino acids are often referred to as the 'building blocks of proteins,' needed for building proteins, hormones, and neurotransmitters. are compounds that play many critical roles in your body. You need them for vital processes such as building proteins, hormones, and neurotransmitters. Amino acids are concentrated in protein-rich foods such as meat, fish, and soybeans, and foods that contain all nine essential amino acids are called complete proteins. Peptides are short proteins, and come in the form of hormones such as follicle-stimulating hormone (FSH), and creatine and collagen. What they aim to help: Amino acid supplements may help with various issues—such as L-arginine for blood flow and inflammation; tryptophan for mood and sleep; and valine, leucine, and isoleucine to help with energy and athletic performance. Taking collagen supplements may help strengthen nails and bones, while people take creatine for boosting workouts and building muscle growth. Risks: Side effects of taking either can range from toxicity and gastrointestinal issues to effects on brain function muscle protein balance. Creatine may cause muscle cramps and digestive problems (and may not have many benefits), while tryptophan may cause dizziness, headache, or nausea. And again, as with all supplements, the U.S. Food and Drug Administration regulates them, but doesn't approve them for safety or effectiveness before they are sold to the public. What it is: Hyperbaric oxygen therapy in a medical-grade, FDA-approved chamber lets you breathe pure oxygen—as opposed to everyday air, which is just 21% oxygen mixed with nitrogen. Hyperbaric oxygen is also highly pressurized, thereby allowing the lungs to take more in. Home chambers (used by folks including Lebron James, LeAnn Rimes, and Mayim Bialik), as well as those offered in many wellness clinics, do not deliver 100% oxygen. Instead, they use regular air that is 30% more pressurized than normal for what's known as 'mild hyperbarics.' What it aims to help: The FDA has been regulating HBOT chambers since 1976, and has officially cleared 13 medical conditions—such as decompression sickness, burns, radiation injury, and certain wounds—for such treatment. But it's used off-label for many other reasons, including concussions, traumatic brain injury, long COVID, age reversal, stroke recovery, fibromyalgia, and improved brain function, many of which are being looked at in ongoing clinical trials. Risks: For medical-grade chambers, risks include ear and sinus pain, middle ear injuries, temporary vision changes, and lung collapse, which is rare, according to the FDA. For mild hyperbarics, risks include potential exposure to toxic oils from some compressors, carbon dioxide buildup that brings a risk of hypoxia inside the chamber—or, according to some experts and a body of inconclusive evidence, that the treatment may simply be ineffective. This story was originally featured on
